{
"id":"mk19_a_np_q015",
"number":15,
"bookId":"np",
"correctAnswer":"A",
"title":"Question 15",
"stimulus":[
{
"type":"p",
"hlId":"bfe39e",
"children":[
"A 68-year-old man is evaluated in the emergency department for generalized weakness that began 12 hours ago after ingesting a bottle of magnesium citrate for constipation. He has hypertension, hyperlipidemia, and stage G4 chronic kidney disease. Medications are furosemide, nifedipine, and simvastatin."
]
},
{
"type":"p",
"hlId":"c1161f",
"children":[
"On physical examination, blood pressure is 102/64 mm Hg, and pulse rate is 50/min; other vital signs are normal. Muscle strength is 4/5 diffusely. Reflexes are absent throughout. The remainder of the examination is normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"1a4da4",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Calcium, serum",
"children":[
"Calcium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"b47e6a",
"class":"cell text l",
"children":[
"8.4 mg/dL (2.1 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"06bd48",
"class":"cell text l",
"children":[
"5.5 mg/dL (486.2 Âµmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"fad908",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Magnesium, serum",
"children":[
"Magnesium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"233c7f",
"class":"cell text l",
"children":[
"6.8 mg/dL (2.8 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"a4922e",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Phosphorus, serum",
"children":[
"Phosphorus"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"4db880",
"class":"cell text l",
"children":[
"5.5 mg/dL (1.8 mmol/L)"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"c4ff97",
"children":[
"Which of the following is the most appropriate immediate treatment?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Intravenous calcium gluconate"
}
},
{
"letter":"B",
"text":{
"__html":"Intravenous furosemide"
}
},
{
"letter":"C",
"text":{
"__html":"Intravenous sodium bicarbonate"
}
},
{
"letter":"D",
"text":{
"__html":"Oral patiromer"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"5291b1",
"children":[
"Hypermagnesemia decreases neural transmission, resulting in weakness, and blocks both calcium and potassium channels, resulting in hypotension and bradycardia."
]
},
{
"type":"keypoint",
"hlId":"052402",
"children":[
"Symptomatic hypermagnesemia (serum magnesium level >4.8 mg/dL [2.0 mmol/L]) is immediately treated with intravenous calcium gluconate while awaiting hemodialysis."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"e68a63",
"children":[
"The most appropriate immediate treatment is intravenous calcium gluconate (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). Hypermagnesemia is defined by a serum magnesium level of >2.4 mg/dL (0.99 mmol/L). Hypermagnesemia occurs infrequently and most commonly results from excessive intake in the setting of decreased kidney function. Laboratory analysis often shows hypocalcemia. In patients with significant kidney disease, use of magnesium laxatives can cause significant elevation of serum magnesium levels and should be avoided in these patients. Many medications such as antacids and magnesium sulfate used in the treatment of refractory asthma and preeclampsia are other sources of magnesium. Hypermagnesemia decreases neural transmission, resulting in weakness, as seen in this patient, which can progress to paralysis. Hypermagnesemia also blocks calcium and potassium channels, resulting in hypotension and bradycardia. These effects become apparent when the serum magnesium level is >4.8 mg/dL (2.0 mmol/L). Prevention is the key to management of hypermagnesemia by avoiding magnesium-containing medications in patients with reduced kidney function. The immediate treatment for symptomatic hypermagnesemia is intravenous calcium gluconate. Calcium rapidly antagonizes the cardiovascular and neuromuscular effects of hypermagnesemia. This will allow time to set up and initiate hemodialysis, which is the definitive treatment to lower magnesium levels in patients with severe hypermagnesemia."
]
},
{
"type":"p",
"hlId":"c02338",
"children":[
"In patients with normal kidney function, intravenous furosemide (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
"), a loop diuretic, will increase kidney magnesium excretion; treatment would not be beneficial in this patient with late-stage chronic kidney disease."
]
},
{
"type":"p",
"hlId":"617456",
"children":[
"Intravenous sodium bicarbonate (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") is associated with a decrease in ionized calcium. Although in vitro studies suggest a similar effect on ionized magnesium, human studies have not been done to support the use of sodium bicarbonate in the treatment of hypermagnesemia."
]
},
{
"type":"p",
"hlId":"33b713",
"children":[
"Patiromer (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is a cation exchanger that is used to manage chronic elevations of serum potassium. Although patiromer has been associated with hypomagnesemia, this agent has a relative slow onset of action (1 to 4 hours) and would not be effective acutely and thus not an appropriate treatment for this patient."
]
}
],
"relatedSection":"mk19_a_np_s2_5_2_2",
"objective":{
"__html":"Treat hypermagnesemia in a patient with chronic kidney disease."
},
"references":[
[
"Reddy ST, Soman SS, Yee J. Magnesium balance and measurement. Adv Chronic Kidney Dis. 2018;25:224-229. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29793660",
"target":"_blank"
},
"children":[
"PMID: 29793660"
]
},
" doi:10.1053/j.ackd.2018.03.002"
]
],
"hospitalist":true,
"hvc":false,
"peerComparison":{
"A":71,
"B":17,
"C":7,
"D":4,
"E":0
},
"hlIds":[
"bfe39e",
"c1161f",
"a462a3",
"1a4da4",
"b47e6a",
"f461b2",
"06bd48",
"fad908",
"233c7f",
"a4922e",
"4db880",
"c4ff97",
"5291b1",
"052402",
"e68a63",
"c02338",
"617456",
"33b713"
]
}